Related Experiment Video
Updated: Jul 6, 2026
07:45
An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
Published on: October 21, 2014
Metachromatic leukodystrophy: genetics, pathogenesis and therapeutic options.
1Institut für Physiologische Chemie, Rheinische-Friedrich-Wilhems Universität Bonn, Bonn, Germany. gieselmann@institut.physiochem.uni-bonn.de
Acta Paediatrica (Oslo, Norway : 1992)
|May 28, 2008
Summary
Metachromatic leukodystrophy (MLD) is a genetic disorder causing neurological damage due to arylsulfatase A (ASA) deficiency. Recent advancements in animal models are paving the way for promising new MLD therapies and clinical trials.
Area of Science:
- Biochemistry
- Genetics
- Neuroscience
Background:
- Metachromatic leukodystrophy (MLD) is a severe lysosomal storage disease.
- It results from arylsulfatase A (ASA) deficiency, leading to sulphatide accumulation and demyelination.
- Over 110 mutations in the ASA gene are known, influencing disease severity and onset.
Purpose of the Study:
- To review the current understanding of MLD.
- To highlight the development and utility of animal models for MLD research.
- To discuss the progression towards therapeutic interventions for MLD.
Main Methods:
- Analysis of genetic mutations in the ASA gene.
- Development and characterization of ASA-deficient mouse models.
- Utilizing transgenic approaches to create improved MLD animal models.
- Application of therapeutic strategies including enzyme replacement and gene therapy in animal models.
Main Results:
- ASA-deficient mice exhibit sulphatide storage and neurological symptoms, but lack demyelination.
- An improved transgenic mouse model now mirrors key pathological features of human MLD.
- Animal studies have successfully tested enzyme replacement, gene therapy, and viral vector delivery.
Conclusions:
- MLD was historically untreatable with a poor prognosis.
- Advances in genetic and biochemical research, coupled with animal models, have spurred the first clinical trials.
- These developments offer hope for improved patient outcomes in MLD treatment.
Related Concept Videos
01:22Lysosomal Hydrolases
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...